The metabolic syndrome and its components are differentially associated with chronic diseases in a high-risk population of 350 000 adults: A cross-sectional study

Metabolic syndrome and cardiovascular disease among adult cancer patients: results from NHANES 2007-2018

BACKGROUND

Metabolic syndrome (MetS) is a risk factor for cardiovascular disease (CVD), and CVD is a major challenge for cancer patients. This study aimed to investigate the prevalence and association of MetS and CVD among adult cancer patients.

METHODS

This cross-sectional study included cancer patients aged > 18 years from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. The prevalence of MetS and CVD was calculated using weighted analysis. Multivariable logistic regression was used to assess the association between MetS and CVD.

RESULTS

The study included 2658 adult cancer patients, of whom 1260 exhibited MetS and 636 had CVD. The weighted prevalence of MetS and CVD in cancer patients was 45.44%, and 19.23%, respectively. Multivariable logistic regression showed a 79% increased risk in higher CVD prevalence in cancer patients with MetS, with the OR (95% CI) of 1.79 (1.31, 2.44). Notably, obesity, elevated blood pressure (BP), high glucose, and low high density lipoprotein cholesterol (HDL-C) in the MetS components were significantly associated with higher CVD prevalence after adjusting for covariates. Moreover, the risk of CVD prevalence in cancer patients increased with more MetS components. Notably, MetS was more strongly linked to CVD in patients aged < 65 and women.

CONCLUSIONS

Among adult cancer patients, over two-fifths (45.44%) were estimated to have MetS, while about one-fifth (19.23%) were considered to have CVD. Notably, obesity, elevated BP, high glucose, low HDL-C, and higher number of MetS components were found to be significantly associated with higher CVD prevalence among cancer adults. Cancer patients under 65 and women with MetS may be at increased risk of CVD.

Metabolic syndrome, genetic susceptibility, and risk of chronic obstructive pulmonary disease: The UK Biobank Study

AIM

To investigate the effect of metabolic syndrome (MetS), genetic predisposition, and their interactions, on the risk of developing chronic obstructive pulmonary disease (COPD).

METHODS

Cohort analyses included 287 868 participants from the UK Biobank Study. A genetic risk score for COPD was created using 277 single nucleotide polymorphisms. Cox proportional hazard models were used to evaluate the hazard ratios (HRs) with 95% confidence intervals (CIs) for COPD in relation to exposure factors.

RESULTS

During 2 658 936 person-years of follow-up, 5877 incident cases of COPD were documented. Compared with participants without MetS, those with MetS had a higher risk of COPD (HR 1.24, 95% CI 1.17-1.32). Compared to participants with low genetic predisposition, those with high genetic predisposition had a 17% increased risk of COPD. In the joint analysis, compared with participants without MetS and low genetic predisposition, the HR for COPD for those with MetS and high genetic predisposition was 1.50 (95% CI 1.36-1.65; P < 0.001). However, no significant interaction between MetS and genetic risk was found.

CONCLUSIONS

Metabolic syndrome was found to be associated with an increased risk of COPD, regardless of genetic risk. It is crucial to conduct further randomized control trials to determine whether managing MetS and its individual components can potentially reduce the likelihood of developing COPD.

The insulin sensitivity Mcauley index (MCAi) is associated with 40-year cancer mortality in a cohort of men and women free of diabetes at baseline

Background

The association between insulin resistance and cancer-mortality is not fully explored. We investigated the association between several insulin sensitivity indices (ISIs) and cancer-mortality over 3.5 decades in a cohort of adult men and women. We hypothesized that higher insulin resistance will be associated with greater cancer-mortality risk.

Methods

A cohort of 1,612 men and women free of diabetes during baseline were followed since 1979 through 2016 according to level of insulin resistance (IR) for cause specific mortality, as part of the Israel study on Glucose Intolerance, Obesity and Hypertension (GOH). IR was defined according to the Mcauley index (MCAi), calculated by fasting insulin and triglycerides, the Homeostatic Model Assessment (HOMA), the Matsuda Insulin Sensitivity Index (MISI), and the Quantitative Insulin Sensitivity Check Index (QUICKI), calculated by plasma glucose and insulin.

Results

Mean age at baseline was 51.5 ± 8.0 years, 804 (49.9%) were males and 871 (54.0%) had prediabetes. Mean follow-up was 36.7±0.2 years and 47,191 person years were accrued. Cox proportional hazard model and competing risks analysis adjusted for age, sex, country of origin, BMI, blood pressure, total cholesterol, smoking and glycemic status, revealed an increased risk for cancer-mortality, HR = 1.5 (95% CI: 1.1–2.0, p = 0.005) for the MCAi Q₁ compared with Q_2-4. No statistically significant associations were observed between the other ISIs and cancer-mortality.

Conclusion

The MCAi was independently associated with an increased risk for cancer-mortality in adult men and women free of diabetes and should be further studied as an early biomarker for cancer risk.

Adesão ao tratamento anti-hipertensivo e ocorrência de Síndrome Metabólica

RESUMO Objetivo Analisar a associação entre a adesão ao tratamento anti-hipertensivo e a ocorrência de Síndrome Metabólica em pacientes hipertensos de uma unidade de atenção primária à saúde. Método Estudo analítico com corte transversal realizado com 306 pacientes hipertensos de uma Unidade de Atenção Primária à Saúde localizada na cidade de Fortaleza-CE. Resultados Dos participantes do estudo 74,2% eram do sexo feminino, média 61,8 ± 11,9 anos e dentro da faixa etária de 54 a 69, 77,1% raça/cor parda, 60,8% com nível fundamental incompleto ou completo e 70,6% com renda familiar entre 1 e 2 salários mínimos. Dos hipertensos avaliados, 41,5% apresentaram Síndrome Metabólica e 76,5% apresentava aderência parcial ao tratamento anti-hipertensivo. Na avaliação estatística da associação entre as variáveis foi verificado não existir (p = 0,149 e p = 0,642). Os valores referentes à adesão ao tratamento anti-hipertensivo eram iguais, tanto nos pacientes com Síndrome Metabólica como dos que não apresentavam essa condição. Conclusão e implicações para a prática A adesão terapêutica anti-hipertensiva alta e parcial foi prevalente. A frequência de Síndrome Metabólica entre os hipertensos em estudo foi elevada. Portanto, medidas de prevenção para doenças cardiovasculares e alcance das metas terapêuticas devem ser implementas continuamente. Um desafio a ser superado pelos profissionais e serviços de saúde.

Weight gain, but not macronutrient intake, modifies the effect of dietary branch chain amino acids on the risk of metabolic syndrome

AIMS

The aim of this study was to investigate whether both weight change and the background intakes of macronutrient modulate the association between dietary branch chain amino acids (BCAAs) and the risk of metabolic syndrome (MetS).

METHODS

This prospective study was conducted within the framework of theTehranLipidand Glucose Study. BCAA intakes were collected using a valid and reliable semi-quantitative food frequency questionnaire. MetS components were defined according to the modified national Cholesterol Education Program Adult Treatment Panel III. Weight change was categorized as weight gain (≥ or <7% over 8.9 year follow-up). Dietary fat and carbohydrate intake were categorized as above/below the median intake.

RESULTS

Among participants with weight gain ≥ 7% during follow-up, intakes of both dietary BCAAs and its various sources (below or above the median intake) were associated with higher risk of MetS, compared with subjects with lower intakes of BCAAs and weight change ≤ 7%. Background dietary fat and carbohydrate did not modify the association of dietary BCAAs and its various sources with the risk of MetS.

CONCLUSIONS

Weight change, but not dietary macronutrient intake, modulates the association between dietary BCAAs and risk of MetS among adults.

The Impact of Metabolic Syndrome and Lifestyle Habits on the Risk of the First Event of Cardiovascular Disease: Results from a Cohort Study in Lithuanian Urban Population

Background and Objectives: In recent years, the impact of individual risk factors on mortality from cardiovascular diseases (CVD) has been often investigated. However, there is a lack of studies that have evaluated the relationship between lifestyle habits, metabolic syndrome, and their combined influence on the first event of CVD. The aim of this study was to investigate the impact of metabolic syndrome and lifestyle habits on the risk of the first event of CVD in a Lithuanian urban population. Materials and Methods: The presented data were collected from a survey that was carried out within the framework of the international project Health, Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE). For statistical analysis, 4257 participants aged 45–72 years were selected (with a follow-up of 11 years). Results: The findings from the Cox proportional hazards regression multivariable analysis showed that metabolic syndrome, current smoking status, and former smoking status increased the risk of the first event of CVD among men (with respective hazard ratios (HR) of 1.53, 1.94, and 1.43; p < 0.01). In women, metabolic syndrome increased the risk of the first event of CVD (HR = 1.56; p = 0.001), while the increased consumption of fresh vegetables and fruits decreased the risk of the first event of CVD (HR = 0.80; p = 0.003). Multivariable logistic regression analysis results show that a level of increased physical activity by one hour can be linked to a lower risk of metabolic syndrome by 2% among men (odds ratio (OR) = 0.98; p = 0.001). Conclusions: Metabolic syndrome and lifestyle habits including cigarette smoking in men and low consumption of fresh vegetables and fruits in women are strong predictors of the first event of CVD.

Dihydromyricetin Attenuates Metabolic Syndrome And Improves Insulin Sensitivity By Upregulating Insulin Receptor Substrate-1 (Y612) Tyrosine Phosphorylation In db/db Mice

PURPOSE

Dihydromyricetin (DHM), the main bioactive flavonoid in vine tea, exerts multiple health beneficial effects. This work aimed to identify whether a naturally derived flavonoid product, DHM, can significantly attenuate metabolic syndrome and improve insulin sensitivity.

METHODS

10-week-old db/db mice were randomly assigned to receive the antidiabetic agent metformin (Met, 50 mg/kg BW), DHM (1.0 g and 0.5 g/kg BW) or placebo and were simultaneously fed a high-fat diet for 8 weeks. The general status of the animals was observed and recorded daily, body weight and blood glucose levels were measured weekly, during the experimental period. On day 55, the oral glucose tolerance test (OGTT) was performed. After OGTT, all animals were anesthetized and sacrificed by cervical decapitation. Blood samples were collected in tubes to detect plasma insulin and the biochemical parameters of lipid metabolism. Pancreas histological changes and islet fibrosis were demonstrated by H&E staining and Masson staining, respectively. Moreover, the expression of insulin receptor substrate-1 and phosphorylated insulin receptor substrate-1 in the insulin signaling pathway was detected by Western blot assay.

RESULTS

The oral administration of DHM (1.0 g and 0.5 g/kg BW) reduced the fasting blood glucose, serum insulin, and glycated hemoglobin levels and the insulin resistance (HOMA-IR) index. Furthermore, DHM intervention decreased body weight and the serum lipid profile. In addition, DHM treatment also markedly decreased the relative abdominal fat weight. Western blot analysis indicated that DHM upregulated the IRS-1 (Y612) tyrosine phosphorylation, improving insulin resistance. Treatment with dihydromyricetin attenuated the progression of insulin resistance and pancreatic fibrosis in fatty db/db mice.

CONCLUSION

In summary, we determined the antimetabolic syndrome effect of DHM in db/db obese mice. DHM upregulates the IRS-1 (Y612) tyrosine phosphorylation, improving insulin resistance. Therefore, DHM is a promising therapeutic candidate for the control of metabolic syndrome.